Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study

Journal of Pain and Symptom Management

Volumn 20, Issue 4, 2000, Pages 246-252

  Mercadante, Sebastiano ^a,b   Arcuri, Edoardo ^c   Tirelli, Walter ^c   Casuccio, Alessandra ^d  

^a Anesthesia and Intensive Care Unit   (Italy)

^b LA MADDALENA CANCER CENTER   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Adverse effects; Cancer pain; Ketamine; Neuropathic pain; NMDA antagonist; Opioid response; Randomized controlled epidemiologic study

Indexed keywords

DIAZEPAM; KETAMINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; FEMALE; HALLUCINATION; HUMAN; MALE; NAUSEA; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; VOMITING; XEROSTOMIA;

ADULT; AGED; CENTRAL NERVOUS SYSTEM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HALLUCINATIONS; HUMANS; KETAMINE; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN MEASUREMENT; PAIN, INTRACTABLE; RECEPTORS, N-METHYL-D-ASPARTATE; SLEEP STAGES; TREATMENT OUTCOME;

EID: 0033797279     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(00)00194-9     Document Type: Article

References (27)

1. Hanks G.W., Justins D.M. Cancer pain. management Lancet. 339:1992;1031-1036.
2. Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer. 34:1998;627-631.
3. Portenoy R.K., Foley K.M., Inturrisi C.E. The nature of opioid responsiveness and its implications for neuropathic pain. new hypotheses derived from studies of opioid infusions Pain. 43:1990;273-286.
4. Coderre T.J., Katz J., Vaccarino A.L.et al. Contribution of central neuroplasticity to pathological pain. review of clinical and experimental evidence Pain. 52:1993;259-285.
5. Mao J., Price D.D., Mayer D.J. Experimental mononeuropathy reduces the antinociceptive effects of morphine. implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain Pain. 61:1995;353-364.
6. Aredt-Nielsen L., Peterson-Felix S., Fischer M.et al. The effect of N-methyl-D-aspartate antagonists (ketamine) on single and repeated nociceptive stimuli. a placebo-controlled experimental human study Anesth Analg. 81:1995;63-68.
7. Ghorpade A., Advokat C. Evidence of a role for N-methyl-D-aspartate (NMDA) receptors in the facilitation of tail withdrawal after spinal transection. Pharmacol Biochem Behav. 48:1994;175-181.
8. Backonja M., Arndt M., Gombar K.A.et al. Response of chronic neuropathic pain syndromes to ketamine. a preliminary study Pain. 56:1994;51-57.
9. Cherry D.A., Plummer J.L., Gourlay G.K.et al. Ketamine as an adjunct to morphine in the treatment of pain. Pain. 62:1995;119-121.
10. Persson J., Axelsson G., Hallin R.G.et al. Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain. 60:1995;217-222.
11. Ogawa S., Kanamaru T., Noda K.et al. Intravenous microdrip infusion of ketamine in subanaesthetic doses for intractable terminal cancer pain. Pain Clin. 7:1994;125-129.
12. Oshima F., Tei K., Kayazawa H.et al. Continuous subcutaneous injection of ketamine for cancer pain. Can J Anaesth. 37:1990;385-392.
13. Edmonds P, Davis C. Experience of the use of subcutaneous ketamine in patients with cancer-related neuropathic pain. Presented at the 4th Congress of the European Association for Palliative Care, Barcelona, December 6-9, 1995. Eur J Palliat Care 1995:68 (abstract).
14. Edmonds P, Davis C. Experience of the use of subcutaneous ketamine in patients with cancer-related neuropathic pain. Presented at the 4th Congress of the European Association for Palliative Care, Barcelona, December 6-9, 1995. Eur J Palliat Care 1995:68 (abstract).
15. Clark J.L., Kalan G.E. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patients. J Pain Symptom Manage. 10:1995;310-314.
16. Mercadante S., Lodi F., Sapio M.et al. Long-term ketamine subcutaneous infusion in neuropathic cancer pain. J Pain Symptom Manage. 10:1995;564-568.
17. Pereira J., Hanson J., Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer. 79:1997;835-842.
18. Sosnowski M, Lossignol D, Fodderie L. Reversibility of opioid insensitive pain. 7th World Congress on Pain, August 22-27, 1993. 1993:16 (abstract).
19. Luczak J., Dickenson A.H., Kotlinska-Lemieszek A. The role of ketamine, an NMDA receptor antagonist, in the management of pain. Progr Palliat Care. 3:1995;127-134.
20. Laird D., Lovel T. Paradoxical pain. Lancet. 341:1993;241.
21. Twycross R. Pain relief in advanced cancer. 1994;476-479 Pittman Books Limited, London.
22. Fass J., Bares R., Hermsdorf V.et al. Effects of intravenous ketamine on gastrointestinal motility in the dog. Intensive Care Med. 21:1995;584-589.
23. Bruera E., Miller L., McCallion J.et al. Cognitive failure in patients with terminal cancer. a prospective study J Pain Symptom Manage. 7:1992;192-195.
24. Bruera E., Schoeller T., Montejo G. Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain. 48:1992;397-399.
25. Price D.D., Mao J., Frenk H.et al. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain. 59:1994;165-174.
26. McQuay H.J., Carroll D., Jadad A.R.et al. Dextromethorphan for the treatment of neuropathic pain. a double-blind randomised controlled crossover trial with integral n-of-1 design Pain. 59:1994;127-133.
27. Mercadante S., Casuccio A., Genovese G. Ineffectiveness of dextromethorphan in cancer pain. J Pain Symptom Manage. 16:1998;317-322.